Literature DB >> 9852117

Identification of serine 356 and serine 363 as the amino acids involved in etorphine-induced down-regulation of the mu-opioid receptor.

A L Burd1, R El-Kouhen, L J Erickson, H H Loh, P Y Law.   

Abstract

Agonist-induced internalization of G protein-coupled receptors is influenced by many structural determinants including the carboxyl tail. To investigate the role of serine and threonine residues within the carboxyl tail, several mutants were constructed by truncating the carboxyl tail of the hemagglutinin-tagged mu-opioid receptor, thereby removing serines and threonines systematically. Neuro2A cells stably expressing the truncated receptors did not exhibit a significant alteration in the affinity of [3H]diprenorphine or etorphine for the receptor or the potency of etorphine to inhibit forskolin-stimulated adenylyl cyclase activity. Chronic etorphine treatment resulted in a time-dependent down-regulation of all the truncated receptors, except MOR1TAG355D, thus revealing the importance of the four amino acids between Ser355 and Glu359 (STIE). Surprisingly, deletion of the STIE sequence resulted in a receptor that down-regulated the same as the wild-type receptor. The involvement of multiple amino acids within the carboxyl tail was demonstrated by combining alanine substitutions of several putative G-protein-coupled receptor kinase phosphorylation sites. Systematic analysis of these receptors indicated that mutation of Ser356 and Ser363 to alanine attenuated agonist-mediated down-regulation. The magnitude of etorphine-induced phosphorylation of this mutant receptor, however, was similar to that of the wild-type mu-opioid receptor. Thus, phosphorylation of the carboxyl tail of the mu-opioid receptor is not an obligatory event for etorphine-induced down-regulation of the receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852117     DOI: 10.1074/jbc.273.51.34488

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Hierarchical phosphorylation of delta-opioid receptor regulates agonist-induced receptor desensitization and internalization.

Authors:  O M Kouhen; G Wang; J Solberg; L J Erickson; P Y Law; H H Loh
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

2.  Protein kinase C-mediated phosphorylation of the μ-opioid receptor and its effects on receptor signaling.

Authors:  Bo Feng; Zhihua Li; Jia Bei Wang
Journal:  Mol Pharmacol       Date:  2011-01-06       Impact factor: 4.436

3.  Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells.

Authors:  Christian Doll; Florian Pöll; Kenneth Peuker; Anastasia Loktev; Laura Glück; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

4.  Agonist Binding and Desensitization of the μ-Opioid Receptor Is Modulated by Phosphorylation of the C-Terminal Tail Domain.

Authors:  William T Birdsong; Seksiri Arttamangkul; James R Bunzow; John T Williams
Journal:  Mol Pharmacol       Date:  2015-05-01       Impact factor: 4.436

5.  Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies.

Authors:  Christian Doll; Jens Konietzko; Florian Pöll; Thomas Koch; Volker Höllt; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 6.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

7.  Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A.

Authors:  Irma Onoprishvili; Eric J Simon
Journal:  Brain Res       Date:  2007-08-16       Impact factor: 3.252

8.  Identification of phosphorylation sites in the COOH-terminal tail of the μ-opioid receptor.

Authors:  Ying-Ju Chen; Sue Oldfield; Adrian J Butcher; Andrew B Tobin; Kunal Saxena; Vsevolod V Gurevich; Jeffrey L Benovic; Graeme Henderson; Eamonn Kelly
Journal:  J Neurochem       Date:  2012-11-30       Impact factor: 5.372

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.